Is interleukin‐27 a real candidate for immunotherapies of multiple sclerosis?
Clinical and Experimental Neuroimmunology · 2013
DOI: 10.1111/cen3.12014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Neuroimmunology, 2013. Verfasst von Yoh Matsumoto. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
As interleukin ( IL )‐27 has immunosuppressive effects and blocks T h17 differentiation, some researchers have investigated the possibility of the use of IL ‐27 for treatment of autoimmune diseases including multiple sclerosis. However, it has now been shown that the functions of IL ‐27 are more pleomorphic than expected. Therefore, more detailed analysis is necessary before entering this phase.
Zitieren
APA
Matsumoto, Y. (2013). Is interleukin‐27 a real candidate for immunotherapies of multiple sclerosis?. Clinical and Experimental Neuroimmunology. https://doi.org/10.1111/cen3.12014
Vancouver
Matsumoto Y. Is interleukin‐27 a real candidate for immunotherapies of multiple sclerosis?. Clinical and Experimental Neuroimmunology. 2013. doi:10.1111/cen3.12014
BibTeX
@article{Matsumoto2013,
author = {Matsumoto, Yoh},
title = {Is interleukin‐27 a real candidate for immunotherapies of multiple sclerosis?},
journal = {Clinical and Experimental Neuroimmunology},
year = {2013},
doi = {10.1111/cen3.12014}
}
EUVIMED